Capability

Pharmaceutical manufacturing in Singapore

Manufacture of small-molecule active pharmaceutical ingredients (APIs) by chemical synthesis and their formulation into oral solid dose and other finished forms. Buyers select on API-versus-finished-dose scope, containment and high-potency (HPAPI) capability, batch-versus-continuous technology, and PIC/S GMP licensing under the Health Sciences Authority.

Small-molecule pharmaceutical manufacturing is the older, deeper half of Singapore's drug-making base — the making of active pharmaceutical ingredients (APIs) by chemical synthesis and their formulation into oral solid dose (OSD) and other finished forms. It is the pillar that first drew the industry here: Pfizer, GSK, MSD, Novartis and AbbVie all run API plants at Tuas Biomedical Park and Jurong, and pharmaceuticals historically supplied the large majority of Singapore's biomedical-sciences manufacturing output, which runs to roughly S$18–20 billion a year. The regulator is the Health Sciences Authority (HSA), which issues the Manufacturer's Licence for Therapeutic Products (TPML) and enforces PIC/S GMP; for a buyer or partner, that licence plus a facility's inspection history is the price of entry. Tuas Biomedical Park itself spans 371 hectares across two phases and remains the physical core of the cluster.

The buyer's decision stack runs on a few axes: API (drug substance) versus finished dose — whether the plant synthesises the molecule, formulates it, or both; containment and potency — standard versus high-potency (HPAPI) and cytotoxic handling for oncology; technology — batch versus continuous and digital manufacturing, which GSK and others have deployed in Singapore under EDB roadmaps; and captive versus contract. The field is a barbell. At one end sit the captive MNC API giants — Pfizer's roughly 22-acre Tuas API plant (extended with a US$743 million investment) making molecules such as pregabalin; GSK's Jurong and Tuas chemical operations producing ten-plus APIs plus a first-in-Singapore high-potency oncology facility; MSD's 72-acre Tuas hub; Novartis's solid-dose plant; and AbbVie's contained small-molecule API site. At the other end is a small but real homegrown finished-dose tier — Beacons Pharmaceuticals, described as Singapore's largest generic-drug maker with 200-plus products across two PIC/S-GMP plants, and ICM Pharma, a finished-dose and contract manufacturer with 300-plus products. The structural signal is that while small-molecule remains the installed base, most new capital is now flowing to biologics — making the surviving API plants and the homegrown generics makers a scarcer, more defensible set.

Also known as: API manufacturing · active pharmaceutical ingredient manufacturing · small-molecule manufacturing · drug manufacturing · oral solid dose manufacturing · generic drug manufacturing

Capability specifications

Scope: API (drug substance), finished-dose formulation, or both
Dosage forms: Tablets, capsules, liquids, creams, injectables
Containment: Standard, high-potency (HPAPI) and cytotoxic handling
Technology: Batch, continuous and digital manufacturing
Regulatory: HSA manufacturer's licence (TPML); PIC/S GMP

Companies with this capability in Singapore

Pfizer (Singapore)
Runs a small-molecule API plant at Tuas Biomedical Park spanning about 22 acres with close to 400 staff, historically producing APIs including gabapentin and pregabalin; a roughly US$743 million extension of the Tuas API plant, and a Jurong Island Manufacturing Technology & Development Centre supporting global process development.
Website (opens Pfizer (Singapore) in a new tab)
GSK (Singapore)
Operates Singapore's largest vaccines and biologics manufacturing complex at Tuas, and small-molecule chemical and API manufacturing at Jurong and Tuas — historically ten-plus APIs, a Jurong facility deploying continuous and digital manufacturing, and a first-in-Singapore high-potency oncology plant. The Tuas site pairs biologic and vaccine production with small-molecule API.
Website (opens GSK (Singapore) in a new tab)
MSD (Merck & Co)
A 72-acre multi-product Tuas hub whose chemical plant has historically produced small-molecule APIs (including etoricoxib and simvastatin), with a US$500 million programme adding sterile fill-finish and secondary packaging for biologic products — KEYTRUDA (pembrolizumab) vials and GARDASIL 9 syringes. Singapore headcount exceeds 1,800.
Website (opens MSD (Merck & Co) in a new tab)
Novartis Singapore
Operates a biologics drug-substance facility at Tuas built with an investment of over US$500 million — its first biomanufacturing plant in Asia, using cell-culture production — alongside a separate solid-dosage (tablet) small-molecule plant through Novartis Singapore Pharmaceutical Manufacturing (NSPM).
Website (opens Novartis Singapore in a new tab)
AbbVie Operations Singapore
Operates a contained small-molecule API facility (around 120,000 sq m) at Tuas Biomedical Park producing APIs for its immunology and oncology pipelines, alongside bulk biologics drug-substance manufacturing on the same campus, with a further US$223 million committed to expand biologics capacity.
Website (opens AbbVie Operations Singapore in a new tab)
Amgen Singapore Manufacturing
Amgen's first Asian manufacturing site at Tuas Biomedical Park, anchored by a next-generation biologics (monoclonal antibody) drug-substance plant integrating multiple process technologies into one facility at a fraction of the footprint, capital and operating cost of a conventional plant, with a chemical-synthesis (small-molecule API) facility alongside it; the site employs 350-plus staff.
Website (opens Amgen Singapore Manufacturing in a new tab)
Beacons Pharmaceuticals
A homegrown manufacturer described as Singapore's largest generic-pharmaceutical maker, producing 200-plus therapeutics across multiple finished dosage forms from two PIC/S-GMP plants, with fully integrated contract manufacturing.
Website (opens Beacons Pharmaceuticals in a new tab)
ICM Pharma
A Singapore finished-dose manufacturer producing 300-plus products across tablets, capsules, liquids, creams and injectables at a cGMP facility, with contract and OEM manufacturing via its PharmaKoe arm.
Website (opens ICM Pharma in a new tab)

ENQUIRE

Not sure which supplier?

Tell the Singapore Industry Index what you need — this enquiry is tagged to Pharmaceutical manufacturing — and we'll point you to the companies on the record that do it. To reach one company directly, enquire from its profile above.